key: cord-1040413-6fghw91j authors: Usman, AA; Gutsche, JT title: Mechanical Circulatory Support for the Right Ventricle: The Right Ventricle is No Longer Forgotten date: 2022-04-22 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2022.04.020 sha: ac7c744c8ce502cfa48bad1603e58b25df8a2454 doc_id: 1040413 cord_uid: 6fghw91j nan and outflow orifices positioned at the distal tip of the catheter in the pulmonary artery (PA). The cannula is then connected to a centrifugal pump. In this configuration, without an oxygenator, the cannula can be used as a percutaneous RVAD, for ventricular support. When an oxygenator is added to the circuit it can be used not only for right ventricular assist but as an ECMO circuit, often referred to as an oxygenated RVAD. Mechanical circulatory support (MCS) for the RV is an area of intense clinical growth and research. Historically, the RV has persistently baffled physicians. In 1648 Sir William Harvey writes in De Motu Cordis: "Thus the right ventricle may be said to be made for the sake of transmitting blood through the lungs, not for nourishing them." 2 Over time, as cardiac surgery has evolved, in arenas such as heart transplantation and left ventricular assist device placement, complex operations have illustrated that acute RV failure remains the Achilles heel in optimal patient survival. Alternatively, clinicians have learned that surgically mimicking a Fontan circulation, with an RV that is completely bypassed, can be done with relatively few short-term sequelae. The question then remains how important the RV is and when should both medical and MCS options be utilized for acute RV failure. RV failure, in general, is an independent risk factor for morbidity and mortality in a number of clinical conditions including congestive heart failure, ARDS, cardiomyopathies, pulmonary hypertension, and post cardiac surgery. 3, 4 We are now advancing our understanding of the RV and are likely entering an era where the RV is no longer the "forgotten ventricle". 3, 5 Medical support of the RV includes optimization of the RV afterload with PA vasodilators, optimization of the RV loading with diuretics, and direct RV systolic support with inotropic agents such as epinephrine, milrinone, or levosimendan. After exhausting medical therapies for acute RV failure there are two major MCS options: Intracorporeal axial flow devices such as the RP Impella (Abiomed, MA) and extracorporeal centrifugal devices with cannulas and/or grafts that bypass the RV. The vast majority of RV support is temporary. The advantage of the extracorporeal support device includes the ability to introduce an oxygenator. The pulmonary vasculature is exquisitely sensitive to hypoxia and hypercarbia. Both these can be addressed with an inline oxygenator. 6, 7 Understanding RV biomechanics and, in particular, the relationship between the RV and PA is key to identifying different phases of RV dysfunction leading to RV failure and death. COVID ARDS has been found to cause acute pulmonary arterial hypertension and RV dysfunction. 7, 8 Physiologically, RV-PA coupling is determined by end-systolic and pulmonary arterial elastance. 9 In acute pulmonary hypertensive states, RV contractility increases to maintain RV-PA coupling and the RV elastance to PA elastance ratio remains between 1.5-2. 9 In COVID ARDS patients develop systemic inflammation, microvascular thrombosis, In their cohort of patients they had 11.1% (2/18) mortality. 13 Both survival outcomes are in sharp distinction from the overall COVID venovenous ECMO survival that has been published which has ranged from the 16.7 -65.0%. 14 In a meta-analysis of 1896 patients from 22 studies of venovenous ECMO support for COVID ARDS the overall mortality was reported to be 37.1% In our own institutional experience, we used an oxygenated RVAD for COVID ARDS in 12 patients. We found three distinct cannulating strategies for these patients. First, we used the Protek Duo RA to PA cannula. Second, we used the novel, Spectrum, dual stage, dual lumen, RV and RA to PA cannula. This cannula was FDA approved in December 2021. Finally, we also used two independent cannulas, inflow from the femoral vein and outflow through a single lumen end hole cannula positioned in the PA from the right internal jugular vein. We found that having three cannulation RV support options increased the armamentarium available to tackle ARDS depending on the clinical situation. Based on our experience and the current literature, a multicenter clinical trial addressing the various cannulation strategies in ARDS should be conducted. Temporary MCS for the RV is an active area of device development. In addition to the new Spectrum cannula, a new axial flow device is on the horizon designed by Abiomed. Currently, the only axial flow catheter for the right side is the RP Impella. The current iteration of the RP Impella is placed from the right femoral vein. The femoral approach is challenging for RV devices, in particular, due to the difficult in navigating the tricuspid and pulmonary valve from the inferior vena cava as well as the distance. Thus, Abiomed has now developed a 23 French right internal jugular RP Impella. This cannula is positioned in similar fashion as a pulmonary artery catheter and can achieve flows up to 4.0 liters per minute. This axial flow device will likely be used by cardiac anesthesiologists to assist separation from cardiopulmonary bypass in those patients with high risk for acute RV failure or for patients who have isolated RV failure or biventricular failure in the cardiothoracic intensive care unit. Ultimately, this catheter will add to the MCS options available to the cardiac anesthesiologist or cardiac intensivist managing acute RV failure. Again, we commend the authors on presenting this unique case report. We are excited to share our cannulating platforms with the readership. We look forward to implementing platforms of RV MCS in the near future and are eagerly anticipating clinical trials that demonstrate the noninferiority of venopulmonary oxygenated RVAD support in ARDS. ☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Right Ventricular Function in Cardiovascular Disease The Forgotten Ventricle The Right Ventricle in ARDS Right Ventricular Dysfunction in Patients with Coronavirus Disease 2019 Supported with Extracorporeal Membrane Oxygenation Persistent Right Ventricle Dilatation in SARS-CoV-2-Related Acute Respiratory Distress Syndrome on Extracorporeal Membrane Oxygenation Support Multi-Beat Right Ventricular-Arterial Coupling Predicts Clinical Worsening in Pulmonary Arterial Hypertension Extracorporeal Membrane Oxygenation with Right Ventricular Assist Device for COVID-19 ARDS Extracorporeal Membrane Oxygenation and Coronavirus Disease 2019-Reply Extracorporeal Membrane Oxygenation with Right Ventricular Assist Device for COVID-19 ARDS Extracorporeal membrane oxygenation for COVID-19: a systematic review and meta-analysis Outcomes by cannulation methods for venovenous extracorporeal membrane oxygenation during COVID-19: A multicenter retrospective study